PRECISION BIOSCIENCES INC — Form 8-K
Filed November 5, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
Precision BioSciences announced Phase 1 ELIMINATE-B data for PBGENE-HBV (hepatitis B gene therapy) showing 100% pgRNA loss to undetectable at 0.4 mg/kg in 6 evaluable patients, including breakthrough efficacy in a hard-to-treat HBeAg-positive patient (pgRNA declined from 5,750 to undetectable). Liver biopsies confirmed cccDNA elimination (1–1.5-log reductions). Safety was favorable across 59 administrations in 25 patients with no dose-limiting toxicities at 0.4 mg/kg; company is initiating global Phase 2 ELIMINATE-B2 in Q1 2027 evaluating monotherapy and combination with antisense oligonucleotide (bepirovirsen). Additionally, PBGENE-DMD (Duchenne muscular dystrophy program) received independent Data Safety Monitoring Board clearance to continue dosing after first patient completed 8-week safety observation with no serious adverse events.
Why this rating
Compelling Phase 1 efficacy and safety data for lead program; pivotal monotherapy and combination pathway validated. Advancing to Phase 2 in near-term; clinical breakthroughs in hard-to-treat population material for $47M market-cap biotech. DMD program safety clearance is secondary positive.
Tradability signal
SHORT
conviction 20/100 · expected -0.49% over 4 hrs
SHORT (fade the pop): stock already ran +15.6% on this news, and positive calls in this cell have historically given the pop back (-0.53% over 4 hrs, n=325). Reversion play, lower conviction by design. Exit plan: HARD stop 8% against entry — 1.4× this stock's measured hourly volatility, fixed, not trailing (trails test terribly on these names) — time exit 4 hrs. (Filing arrived outside market hours — evaluated at the next open with a live quote.)
Derived from this site's own measured outcomes + live price/liquidity at analysis time. An experiment, not investment advice.
Price action (we called it positive)
before filing · preread $8.38 ▼ 4.83% | at our read · unknown $8.80 | +10 min · unknown $10.36 ▲ 17.67% | +30 min · unknown $9.66 ▲ 9.71% | +1 hr · unknown $9.30 ▲ 5.62% | +4 hrs · unknown $9.81 ▲ 11.41% |
The stock had already moved +5.07% between hitting EDGAR and our read finishing — deltas above are measured from our read.
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from November 5, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.